Autolus Therapeutics plc
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
AUTL$1.32+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | |||
|---|---|---|---|
| Note | 2024 | 2023 | |
| Assets | |||
| Current assets: | |||
| Cash and cash equivalents | $227,380 | $239,566 | |
| Marketable securities - Available-for-sale debt securities | 6 | 360,643 | — |
| Restricted cash | 1,425 | 769 | |
| Inventories, net | 7 | 4,138 | — |
| Prepaid expenses and other current assets | 8 | 67,343 | 34,967 |
| Total current assets | 660,929 | 275,302 | |
| Non-current assets: | |||
| Property and equipment, net | 9 | 49,553 | 34,862 |
| Intangible assets, net | 10 | 12,373 | — |
| Prepaid expenses and other non-current assets | 170 | 380 | |
| Operating lease right-of-use assets, net | 19 | 55,498 | 60,791 |
| Long-term deposits | 963 | 983 | |
| Deferred tax asset | 18 | 3,239 | 3,063 |
| Total assets | $782,725 | $375,381 | |
| Liabilities and shareholders' equity | |||
| Current liabilities: | |||
| Accounts payable | 1,969 | 103 | |
| Accrued expenses and other liabilities | 11 | 52,276 | 39,581 |
| Operating lease liabilities, current | 19 | 2,998 | 5,053 |
| Liabilities related to future royalties and milestones, net - current | 12 | 3,500 | — |
| Total current liabilities | 60,743 | 44,737 | |
| Non-current liabilities: | |||
| Operating lease liabilities, non-current | 19 | 49,631 | 47,914 |
| Liabilities related to future royalties and milestones, net - non-current | 12 | 244,600 | 170,899 |
| Other long-term payables | 426 | 357 | |
| Total liabilities | 355,400 | 263,907 | |
| Commitments and contingencies | 20 | ||
| Shareholders' equity: | |||
| Ordinary shares, $0.000042 par value; 490,909,783 shares authorized at December 31, 2024 and 290,909,783 as of December 31, 2023; 266,121,689 and 174,101,361 shares issued at December 31, 2024 and 2023, respectively; 266,125,337 and 174,158,985 shares outstanding at December 31, 2024 and 2023, respectively | 14 | 12 | 8 |
| Deferred shares, £0.00001 par value; 34,425 shares authorized, issued and outstanding at December 31, 2024 and 2023 | 14 | — | — |
| Deferred B shares, £0.00099 par value; 88,893,548 shares authorized, issued and outstanding at December 31, 2024 and 2023 | 14 | 118 | 118 |
| Deferred C shares, £0.000008 par value; 1 share authorized, issued and outstanding at December 31, 2024 and 2023 | 14 | — | — |
| Additional paid-in capital | 1,555,593 | 1,018,902 | |
| Accumulated other comprehensive loss | (29,174) | (28,992) | |
| Accumulated deficit | (1,099,224) | (878,562) | |
| Total shareholders' equity | 427,325 | 111,474 | |
| Total liabilities and shareholders' equity | $782,725 | $375,381 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.